Long-term and Effective Neutralization Against Omicron Sublineages Elicited by Four Platform COVID-19 Vaccines As a Booster Dose

Overview

Journal Cell Discov

Date 2023 Feb 8

PMID 36754955

Authors

Yuemiao Zhang

Meng-Ting Luo

Qingqin Wu

Yun-Xia Wang

Xupu Ma

Guanghong Yan

Si-Hang Zhang

Yanli Chen

Na Wan

Liang Zhang

Dingyun You

Jia Wei

Zijie Zhang

Tai-Cheng Zhou

Affiliations

Soon will be listed here.

Citing Articles

COVID-19 vaccine updates for people under different conditions.

Huang Y, Wang W, Liu Y, Wang Z, Cao B Sci China Life Sci. 2024; 67(11):2323-2343.

PMID: 39083202 DOI: 10.1007/s11427-024-2643-1.

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.

Feng G, Wang Z, He P, Lan Q, Ni L, Yang Y Hum Vaccin Immunother. 2023; 19(2):2262635.

PMID: 37881130 PMC: 10644802. DOI: 10.1080/21645515.2023.2262635.

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.

Liu Y, Lu J, Zhan H, Yuan W, Li X, Kang H Virol Sin. 2023; 38(5):723-734.

PMID: 37487943 PMC: 10590695. DOI: 10.1016/j.virs.2023.07.005.

References

Bertoletti A, Bert N, Tan A . SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity. 2022; 55(10):1764-1778. PMC: 9385766. DOI: 10.1016/j.immuni.2022.08.008. View

Li M, Guo J, Lu S, Zhou R, Shi H, Shi X . Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. Front Immunol. 2021; 12:697074. PMC: 8273614. DOI: 10.3389/fimmu.2021.697074. View

Dai X, Zhao W, Tong X, Liu W, Zeng X, Duan X . Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque. Arch Toxicol. 2022; 96(5):1437-1453. PMC: 8883008. DOI: 10.1007/s00204-021-03221-x. View

Liu H, Zhou C, An J, Song Y, Yu P, Li J . Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. Vaccine. 2021; 39(48):7001-7011. PMC: 8556577. DOI: 10.1016/j.vaccine.2021.10.066. View

Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

Zhang Y, Ma X, Yan G, Wu Y, Chen Y, Zhou Z . Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. EClinicalMedicine. 2022; 54:101680. PMC: 9517939. DOI: 10.1016/j.eclinm.2022.101680. View

Yao L, Zhu K, Jiang X, Wang X, Zhan B, Gao H . Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection. Lancet Infect Dis. 2022; 22(8):1116-1117. PMC: 9212811. DOI: 10.1016/S1473-3099(22)00410-8. View

Collier A, Yu J, McMahan K, Liu J, Chandrashekar A, Maron J . Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines. N Engl J Med. 2021; 385(21):2010-2012. PMC: 8531985. DOI: 10.1056/NEJMc2115596. View

Zhao X, Li D, Ruan W, Chen Z, Zhang R, Zheng A . Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N Engl J Med. 2022; 386(9):894-896. PMC: 8809506. DOI: 10.1056/NEJMc2119426. View

10.

Li G, Zhou Z, Du P, Zhan M, Li N, Xiong X . Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant. Signal Transduct Target Ther. 2022; 7(1):243. PMC: 9295091. DOI: 10.1038/s41392-022-01062-3. View

11.

Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H . Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020; 15(11):3699-3715. DOI: 10.1038/s41596-020-0394-5. View

12.

Cooper C, Davis H, MORRIS M, Efler S, Adhami M, Krieg A . CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004; 24(6):693-701. DOI: 10.1007/s10875-004-6244-3. View